Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
The purpose is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults. Through the support of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare neurodegenerative diseases and exert a broad and positive impact on rare disease drug development.
Wijzigingsgeschiedenis
First seen 28 Sept 2026, last checked 22 Nov 2026. 20 recorded versions.
- 22 Oct 2026 · 1df80d0a3635
- 22 Oct 2026 · 5cd090d8bf17
- 21 Oct 2026 · 87406394c6a6
- 20 Oct 2026 · 58df86eefc7d
- 19 Oct 2026 · 93880d763e04
- 18 Oct 2026 · bd2798370dc1
- 17 Oct 2026 · d3d7da9577ab
- 16 Oct 2026 · 34aa49356283
- 15 Oct 2026 · c989a0b63d98
- 14 Oct 2026 · 3aeeb4e9dfc2
- 13 Oct 2026 · a3ba41855d81
- 12 Oct 2026 · 0e22314dfd95
- 11 Oct 2026 · e992f5aeae17
- 10 Oct 2026 · 5cd108f49038
- 09 Oct 2026 · 68ef067938e1
- 08 Oct 2026 · 7de4404a3f3b
- 07 Oct 2026 · c75680ed621c
- 06 Oct 2026 · 8bb6b9dbc0bb
- 05 Oct 2026 · d7120acd7f7c
- 04 Oct 2026 · 17b601b0b82d